Boston Scientific Corp. (BSX) Company Profile & Statistics

Boston Scientific Corp.
BSX
(NYSE)
Open
67.35
-0.61 (-0.90%)
in:usd•As of: Apr 18, 2024 15:21 UTC -4
Open
68.29
High
68.29
Low
67.22

About Boston Scientific Corp.

CEO

Michael F. Mahoney

Headquarters

300 boston scientific way

marlborough, ma 01752, united states

Auditor

Ernst & Young LLP

Employees

48,000

Share Holders

5,432

Website

www.bostonscientific.com

Industry

medical distributors

Sector

distribution services

Company Overview

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

Boston Scientific Corp. Statistics

Valuation Measures

Market Capitalization ²	98.81B
Enterprise Value	107.05B
Enterprise Value/EBITDA (ttm)	29.76
Price to Earnings Ratio (ttm)	33.23
Price to Book (mrq)	5.11
Price to Sales (ttm)	7.02
Price to Cash (ytd)	23.47

Profitability

Gross Margin (ttm)	69.49%
Operating Margin (ttm)	21.12%
Profit Margin (ttm)	10.99%
Return on Equity (ttm)	15.99%
Return on Invested Capital (ttm)	5.81%
Return on Assets (ttm)	8.87%

Income Statement

Revenue (ttm)	14.24B
Revenue Per Share (ttm)	9.71
Gross Profit (ttm)	9.90B
EBITDA (ttm)³	3.60B
Net Income Avi to Common (ttm)	1.57B
Diluted EPS (ttm)	1.07

Share Statistics

Beta (5Y Monthly)	0.78
52-Week Change	30.50%
S&P500 52-Week Change	20.64%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	1.47B
Dividend Yield	0.00%
Float ⁴	1.46B
% Held by Insiders	0.50%
% Held by Institutions	89.07%

Balance Sheet

Total Cash (mrq)	865.00M
Total Cash Per Share (mrq)	0.59
Total Debt (mrq)	9.10B
Total Debt/Equity (mrq)	46.61%
Current Ratio (mrq)	1.32%
Quick Ratio (mrq)	0.82%
Book Value Per Share (mrq)	13.32

Cash Flow

Operating Cash Flow Per Share (ytd)	1.71
Free Cash Flow (ytd)	1.80B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Boston Scientific Corp.

Trade With A Regulated Broker